Axel Sjöblad
Chief Executive Officer.
Employed June 2019. Born 1967.
Axel Sjöblad has extensive experience in managing and developing global growth companies in medical technology and Life Science and was most recently CEO of BioGaia AB. He previously held CEO positions in Getinge Sverige AB and Gambro Lundia AB with responsibility for subsidiaries running operations in several European countries.
Education: M.Sc. in BA and Executive MBA.
Shareholding: 4 500 shares and 110 000 warrants.*
Marianne Olsson
VP Finance.
Employed 2016. Born 1961.
Marianne Olsson has 25 years of experience from Lund University where she has worked as a department economist, economist and most recently as administrative manager at the Department of Immunotechnology. In addition, Marianne has been a member of the Board of the Faculty of Engineering LTH at Lund University, as well as a member of the management and Department Board at the Department of Immunotechnology.
Education: Certified Financial Manager via FAR.
Shareholding: 114 285 shares and 15 000 warrants.*
Anna Chérouvrier Hansson
VP Sales & Business Development.
Employed 2017. Born 1973.
Anna has extensive experience from marketing, sales and business development from Camurus, Novo Nordisk, Gambro and DuPont among others. In addition, Anna has been a partner at Zitha Consulting, focusing on commercialisation strategy in the pharmaceutical industry and head of Life Science investments at Invest in Skåne.
Education: MSc in European Business Administration and Business Law, BSc in Business Administration.
Shareholding: 19 153 shares (privately and through related parties) and 25 000 warrants.*
Tina Dackemark Lawesson
VP Marketing and Communications.
Employed 2018. Born 1968.
Tina Dackemark Lawesson has long and broad experience from marketing, IR and communication at life science and technology companies in the build-up and growth phase. She has previously held similar positions at INVISIO, CellaVision and Enzymatica among others.
Education: Bachelor of Education (Languages) as well as studies in Journalism.
Shareholding: 15 000 warrants.*
Henrik Johansson
Chief Scientist.
Employed 2014. Born 1982.
Henrik Johansson has more than 10 years of experience of research and development within the fields of cell and molecular biology. He is specialized in in vitro assays for predictive immunotoxicology and is a co-developer of the GARD technology platform, which was first described in detail in his doctoral thesis.
Education: MSc. in Biotechnology Engineering, PhD in Immunotechnology.
Shareholding: 526 shares.*
Åsa Nyhlén
VP Operations.
Employed 2021. Born 1973.
For the past 20 years, Åsa Nyhlén has been responsible for laboratory services in the pharmaceuticals, medical devices and food industries. Åsa has extensive experience of working with international lab partners and building effective and innovative lab organizations. Her past experience includes management positions with Novo Nordisk, Dako and BioGaia.
Education: Msc. in molecular biology.
Shareholding: 6 300 shares.*
Peter Nählstedt
VP Strategy.
With the Company since 2019. Born 1974.
Peter Nählstedt has 20 years of experience from international sales and marketing in leading positions in the life science and industrial sector. Previous experience includes structuring, building and leading globally successful commercial organisations at Probi, Trelleborg Marine Systems and GE Healthcare.
Education: MSc in Chemical Engineering, BSc in Business Administration.
Shareholding: 1 622 shares and 25 000 warrants.**
Helen Olsson
VP HR.
With the Company since 2020. Born 1965.
Helen Olsson has over 20 years of experience in organization development, change management, and both operational and strategic HR, including as VP HR at BioGaia.
Education: Degree in behavioral science.
Shareholding: 1 000 shares.*
Mikael Wahlgren
Legal adviser.
Engaged by the Company since 2016.
Born 1965.
Mikael Wahlgren has previously served as group general counsel for the Alfa Laval Group, corporate counsel for several multinational companies, and as legal counsel for several life science companies. He has been employed with law firm Lindmark Welinder since 2021 where he serves as legal adviser, arbitrator and mediator.
Education: LLM.
Shareholding: 8 571 shares and 11 500 warrants through companies.*
* Euroclear 26/02/2021.
